Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

They work by mimicking the hormone GLP-1, which binds to these receptors and helps to control levels of insulin and glucose in the blood. Acting as GLP-1R agonists (GLP-1RAs), the drugs promote ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

They added that the links between weight loss and discontinuation and between ... 98.6% of these patients were using anti-diabetes medications and 1.4% were using anti-obesity medications.